Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaAdriano Lazzarin, Miklos Salgo, Bonaventura Clotet et al.|New England Journal of Medicine|2003Cited by 653
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infectionRichard Elion, Javier Szwarcberg, Brian Conway et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 41